ZBH

ZIMMER BIOMET HOLDINGS INC

Healthcare • USA

Apr 05 • 04:00PM ET
96.95
+0.22 (+0.23%)
Company Profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest ... read more

Full Time Employees 18,000
Phone 574 267 6131
Website https://www.zimmerbiomet.com
CEO Mr. Ivan Tornos
IPO Date 2001-07-25
Sector Healthcare
Industry Medical - Devices
Address 345 East Main Street, Warsaw, IN 46580
Balance Sheet
Total Cash $1,384,500,000
Total Debt $7,176,300,000
Current Ratio 2.44
Quick Ratio 1.27
Profitability
Gross Margin 71.05%
Net Margin 11.86%
ROE 7.37%
ROA 4.12%
ROIC 5.84%
Balance Sheet
Total Cash $1,384,500,000
Total Debt $7,176,300,000
Current Ratio 2.44
Quick Ratio 1.27
Profitability
Gross Margin 71.05%
Net Margin 11.86%
ROE 7.37%
ROA 4.12%
ROIC 5.84%
Name ZIMMER BIOMET HOLDINGS INC Sector Healthcare Currency USD Relative Volume 2.02 Market Cap 21367
Current Ratio 1.91 Dividend / Share 0.96 EPS 4.43 Revenue 7678600000 P/S 2.8
P/E 23.6 Beta 0.32 Income 903800000 Volume 3852195 Average Volume 1911211
Distance to 200DMA -0.51% 200 DMA 107.89 50 DMA 107.51 ROA 4.2 ROE 7.2
Distance to 50DMA -0.16% Return 1Y -16.7% Return YTD 1.83% Forward PE Qtly Growth YOY
Debt/Eq 0.71 P/B 1.7 Dividend Yield 0.9% Net Margin 11.77% Payout Ratio 21.6
Performance
52 Week Range 21.6%
Distance to 200DMA 0.5%
Day Change Percent $0.48
Performance Week $0.24
Performance Month $0.24
Performance Quarter 2024-09-30
Performance YTD $0.24
Performance Year $0.24

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $569,000,000
Total Debt $6,450,700,000
Current Ratio 1.36%
Quick Ratio 0.57%
Profitability
Gross Margin 71.05%
Net Margin 11.86%
ROE 7.37%
ROA 4.12%
ROIC 5.84%
Valuation
Price to Earnings 21.11
Price to Book 1.56
Price to Sales 2.50
Price to Free Cash Flow -79.03
Dividends
Payout Ratio 20.90%
Dividend Yield 0.99%
Dividend Amount $0.48
Last Dividend Pay Date 2024-09-30
Last Dividend Paid $0.24
Performance
52 Week Range 21.6%
Distance to 200DMA 0.5%
Day Change Percent $0.48
Performance Week $0.24
Performance Month $0.24
Performance Quarter 2024-09-30
Performance YTD $0.24
Performance Year $0.24
Company Profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest ... read more

Full Time Employees 18,000
Phone 574 267 6131
Website https://www.zimmerbiomet.com
CEO Mr. Ivan Tornos
IPO Date 2001-07-25
Sector Healthcare
Address 345 East Main Street, Warsaw, IN 46580
Histogram - Daily

Balance Sheet
Total Cash $569,000,000
Total Debt $6,450,700,000
Current Ratio 1.36%
Quick Ratio 0.57%
Profitability
Gross Margin 0.7180%
Net Margin 0.1430%
ROE 0.09%
ROA 0.05%
Company Profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest ... read more

Full Time Employees 18,000
Phone 574 267 6131
Website https://www.zimmerbiomet.com
CEO Mr. Ivan Tornos
IPO Date 2001-07-25
Sector Healthcare
Address 345 East Main Street, Warsaw, IN 46580
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results
These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results

Zimmer Biomet Holdings, Inc ZBH reported better-than-expected earnings for the first quarter on Monday.

2025-05-06 14:22:26 - benzinga.com
S&P 500 INDEX (SPX) Live: The Markets Turn Cautious in Data-Filled Week
S&P 500 INDEX (SPX) Live: The Markets Turn Cautious in Data-Filled Week

Live Updates Live Coverage Has Ended Markets Pivot to Ford Earnings 4:03 pm by Gerelyn Terzo The markets failed to turn around, ending the trading session lower across the board and ending a multi-ses

2025-05-06 12:05:32 - https://247wallst.com
Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds
Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds

Zimmer Biomet's stock dropped nearly 10% on the back of soft Q1 results. Despite structural tailwinds, Zimmer Biomet's business is struggling in the face of high interest rates, trade tensions and com

2025-05-06 07:39:00 - seekingalpha.com
Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal
Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal

Zimmer Biomet Holdings, Inc ZBH reported first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating the Street estimates of $1.77.

2025-05-05 15:34:30 - benzinga.com
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket

Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.

2025-05-05 14:00:35 - zacks.com
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants David DeMartino - SVP, IR Ivan Tornos - President & CEO Suketu Upadhyay - CFO & EV

2025-05-05 12:05:19 - seekingalpha.com
Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to

2025-05-05 10:35:54 - zacks.com
Zimmer Biomet (ZBH) Surpasses Q1 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) Surpasses Q1 Earnings and Revenue Estimates

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.94 per share a year ago.

2025-05-05 08:40:36 - zacks.com
Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty
Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertain

Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28 , currency volatility, and prop

2025-05-05 07:40:18 - reuters.com
Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics
Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics

Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some o

2025-04-30 10:21:06 - zacks.com
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect

ZBH's Hips business is expected to have witnessed growth on the back of its suite of navigation solutions in direct anterior stems and surgical impactors.

2025-04-22 09:15:33 - zacks.com
Zimmer Biomet Completes Acquisition of Paragon 28
Zimmer Biomet Completes Acquisition of Paragon 28

Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH),

2025-04-21 09:00:00 - prnewswire.com
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financ

WARSAW, Ind. , April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:3

2025-04-10 07:30:00 - prnewswire.com
PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA
PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swic

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc.

2025-04-02 12:47:00 - businesswire.com
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System

Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announc

2025-04-01 07:30:00 - prnewswire.com
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025

Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.

2025-03-26 11:10:22 - zacks.com